Company intelligence / Profile preview

NGM Pharmaceuticals

South San Francisco, California, United States

Ownership: Private
Employees: ~138
Development stage: Other

Overview

NGM Biopharmaceuticals has several candidates that have advanced to Phase 2 clinical trials, including NGM120 for cancer cachexia and hyperemesis gravidarum. Its lead metabolic liver disease program, aldafermin, has shown promising results in nonalcoholic steatohepatitis (NASH), but recent reports indicate a shift in focus to oncology and other unmet needs.

Therapeutic areas: OphthalmologyWomen's HealthGastroenterologyMetabolic DisordersOncology
Modalities: Monoclonal antibodySmall moleculeProteinBiologic
Industry: Biotech

Partnerships

Merck

Beyond the preview

Go deeper on NGM Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NGM Pharmaceuticals.

Explore the full profile